Brief: Eiger Announces Publication Of Phase 2 Prevent Study Results Of Avexitide In Post-Bariatric Hypoglycemia In Journal Of Clinical Endocrinology & Metabolism
23/02/2021 13:38
Feb 23 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER ANNOUNCES PUBLICATION OF PHASE 2 PREVENT STUDY
RESULTS OF
AVEXITIDE IN POST-BARIATRIC HYPOGLYCEMIA IN JOURNAL OF CLINICAL
ENDOCRINOLOGY & METABOLISM
Source text for Eikon: ID:nPn5pHNW9a
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview